Nuvation Bio soared 49% to a nearly four-year high after Wedbush and B Riley issued bullish updates tied to the first full-quarter launch of its ROS1 lung-cancer therapy. The company reported 204 patient starts and outlined revenue potential of $220 million to $2 billion. Fresh glioma data, ex-US partnership plans and an upcoming Phase I/II update boosted sentiment.